Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,844 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma of the Prostate Clear all
Recruiting Not applicable Interventional

AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions

NCT07231627
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bi-parametric MRI-based cascaded deep-learning AI algorithm
Device
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 2, 2026, 11:42 AM EDT
Completed No phase listed Observational

Application of Megavoltage Imaging to Reduce Artifact After Seed Implants

NCT01810627
View directory record Official record
Conditions
Prostate Cancer
Interventions
MVCT
Radiation
Lead sponsor
William St Clair
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 2, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

NCT02379390
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Muscle Shoals, Alabama • Anchorage, Alaska • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 2, 2026, 11:42 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 11:42 AM EDT
Terminated No phase listed Observational

Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients

NCT03740035
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
eHealth for Sedentary Behavior
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

Prostate Cancer Survivors and Exercise and Behavioral Counseling

NCT03191968
View directory record Official record
Conditions
Physical Activity, Cancer of the Prostate, Cognitive Impairment, Quality of Life
Interventions
Supervised Physical Activity Plus Behavioral Counseling, Supervised Physical Activity Plus Exercise Counseling
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

NCT04037358
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, stereotactic ablative radiotherapy (SABR)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

NCT03400150
View directory record Official record
Conditions
Prostate Cancer
Interventions
balloon, Control
Device · Other
Lead sponsor
BioProtect
Industry
Eligibility
18 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Apple Valley, California • Irvine, California • Daytona Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

NCT02064582
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Leuprolide acetate, radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

NCT00887458
View directory record Official record
Conditions
Prostate Cancer
Interventions
Itraconazole 200 mg, Itraconazole 300mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 2, 2026, 11:42 AM EDT
No Longer Available No phase listed Expanded access

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

NCT03501940
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression, Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Radiation · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 2, 2026, 11:42 AM EDT
Terminated Phase 1 Interventional

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

NCT04677855
View directory record Official record
Conditions
Prostate Cancer
Interventions
PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone
Drug
Lead sponsor
Pellficure Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 2, 2026, 11:42 AM EDT
Recruiting Phase 2 Interventional

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

NCT07220720
View directory record Official record
Conditions
Prostate
Interventions
Flotufolastat F 18
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate

NCT00001382
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PROSTVAC
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

NCT01353625
View directory record Official record
Conditions
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma, Chronic Lymphocytic Leukemia, Neoplasm Metastasis
Interventions
CC-115
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 2, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

NCT00448097
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
cetuximab, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning

NCT02681614
View directory record Official record
Conditions
Prostate Cancer
Interventions
Uronav guided biopsy, Magnetic resonance imaging
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Not applicable Interventional

Treatment Decision Intervention for Veterans With Prostate Cancer

NCT00012935
View directory record Official record
Conditions
Prostate Cancer
Interventions
Help with decision making on prostate cancer treatment
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Not applicable Interventional

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

NCT01833208
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Radiation Therapy
Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Buffalo, New York • Cheektowaga, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 2, 2026, 11:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Urology Database and Specimen Bank

NCT00978991
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Erectile Dysfunction, Incontinence
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
87,820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

NCT03404648
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
C-11 choline PET tracer, Gadobutrol, PET/MR scanner
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 2, 2026, 11:42 AM EDT
Completed Not applicable Interventional

Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting

NCT01440855
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Colorectal Cancer, Thoracic Cancer
Interventions
CIS (Cancer Information Service) Information Sheet, Facing Forward booklet
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 2, 2026, 11:42 AM EDT